We at NextPharma are a European contract development and manufacturing organisation (CDMO) specialising in pharmaceutical and nutraceutical development, clinical trial supply, and commercial manufacturing. If you are evaluating CDMO partners, whether for early-stage formulation work, clinical supply, or full-scale commercial production, this page gives you a factual overview of how our network is structured and what we deliver.
The network
We operate 10 specialised manufacturing sites across Europe, each configured as centre of excellence for specific dosage forms, technologies, or regulatory requirements. We supply finished products to customers serving 70 global end markets.
Our network is structured to support the full product lifecycle from the point at which the API is available, covering formulation and analytical development, clinical trial supply, and commercial manufacturing and packaging. Because development, clinical, and commercial activities are coordinated within the same organisation, projects move between stages without external handoffs. Process knowledge, regulatory documentation, and formulation strategy remain continuous throughout.
We support operations with dedicated project management and cross-site technical teams.
Tableted pellets
Granules
Capsules
Bi-layer tablets
Sachets
Tablets and capsules in blisters
Tablets and capsules in bottles
Suspensions, emulsions and solutions (aqueous and alcohol-based)
Syrups and double-point ampoule
For a full overview of our commercial manufacturing capabilities, see commercial manufacturing and packaging services.
All our sites operate under GMP conditions, with quality standards aligned at network level. Our sites are regulated and inspected by a variety of regulatory authorities including the following:
Our quality systems are aligned with ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System), ensuring consistency in process control, documentation, and product quality across development, clinical, and commercial operations.
Each site operates under its own regulatory scope depending on the dosage forms and technologies it handles. Site-specific GMP certificates and inspection history are available on the individual location pages.
EMA
FDA
MHRA
PMDA
Network and site capabilities
Commercial & development activities are supported by specialist centres of excellence across Europe, each aligned to specific technologies and dosage forms.
Operating model
Our network is designed to support pharmaceutical products within a single organisation, avoiding fragmentation across multiple partners. This structure has specific operational implications for your programme:
We align development, clinical supply, and commercial manufacturing within one organisation
Each site operates as a centre of excellence with defined technical ownership
We retain process knowledge within the network
Our supply chains are configured for both clinical and commercial volumes
This model reduces operational complexity for our customers and supports faster, lower-risk progression from development to market supply. For an overview of all our service areas, explore pharmaceutical development, clinical trials services, and analytical and microbiological services.
Sustainability:
Our sustainability programme, NextGreen, focuses on reducing environmental impact across our manufacturing operations. NextPharma has been at this committed neutrality on scope 1 and 2 since the beginning of 2025.
NextPharma has also joined the Science Based Targets initiative (SBTi), extending its commitment to reducing Scope 3 emissions across its value chain. A comprehensive greenhouse gas inventory has been completed, and targeted emissions reduction measures have been identified.
Scope 1 covers direct emissions from sources owned or controlled by NextPharma — fuel combustion in stationary and mobile assets, process emissions, and fugitive emissions. Scope 2 covers indirect emissions from purchased energy, calculated using a market-based approach.
Tracking began in 2021. Since then, the group’s combined Scope 1 and 2 greenhouse gas emissions associated with energy consumption have decreased by 66%, driven by energy efficiency improvements and a progressive switch to renewable energy sources.
This reduction was achieved alongside a 18% decrease in energy consumption. The remaining emissions stem from fossil fuels for which no alternatives are currently available.
Reduction in combined Scope 1 and 2 emissions since 2021
Decrease in energy consumption over the same period
Committed neutrality on Scope 1 and 2 since the beginning of the year
Science Based Targets initiative — Scope 3 commitment
Chief Executive Officer
Joined NextPharma in 2025. He brings over 25 years of international leadership experience across multiple industries, with a strong record in driving customer focus, innovation, operational excellence and profitable growth. Most recently, Ajeeth served as President and General Manager at Trivium Packaging, a global industry leader with 57 sites and around 7,400 employees. Prior to that, he was Senior Vice President of Strategy and Transformation and a member of the Executive Committee at Elementis PLC. His earlier career includes leadership roles with Mondo Minerals, Bain & Co., IBM and PepsiCo.
Ajeeth holds an MBA from IMD in Switzerland, a Master’s in Management from the University of Delhi, and a Bachelor’s in Electrical Engineering from Delhi Technological University.
Chief Financial Officer
Sean has 25 years’ experience in financial and international leadership roles, most recently at GKN Automotive, a global automotive technology company, where he drove business transformation efforts as their CFO. Previously, Sean held a variety of financial roles at Amcor, Trinseo, and Air Products & Chemicals. He holds an MBA from Cornell University, is a licensed CPA, and is a CFA charter holder.
Chief Commercial Officer
Pierre Delavaud, Chief Commercial Officer, joined NextPharma in September 2012 with a strong track record in sales, business development and marketing within the pharmaceutical industry. Prior to joining NextPharma, Pierre held executive sales and business development positions at SkyePharma and spent fourteen years with the Catalent group (and former companies), where he held various senior positions, including Vice President Sales and Business Development Global Pharmaceutical Softgels, Vice President Sales and Marketing Pharmaceutical Technologies and Services Europe, as well as General Manager of a manufacturing site. Pierre holds a PhD in Pharmacy.
Chief Operating Officer
Ina Quinn joined NextPharma as Chief Operating Officer in July 2026, bringing close to two decades of operational leadership in the pharmaceutical industry, most recently as Global Head of OSD Operations at Recipharm.
Throughout her career, Ina has built a reputation for transforming operations organisations and building strong, high-performing teams — most recently leading manufacturing operations at Recipharm, and earlier at Novartis, where she held a series of site and global operations roles.
Ina is known for putting customers at the centre of operational decision-making, and for developing teams that deliver consistently for the patients who depend on them. With this track record, she is well placed to drive NextPharma’s next phase of operational growth.
Chief People Officer
Monica Mauri, Chief People Officer, joined NextPharma in 2026. Monica brings several decades of international HR leadership experience. She strengthened performance management and employee engagement practices across the organisation and modernised the HR platform to enhance the day-to-day experience of both managers and employees. Prior to that, at Staples Solutions, Monica led HR across multiple countries, focusing on strengthening core people practices and supporting organisational change. She applied a structured, people-first approach, ensuring clarity and continuity for employees throughout periods of transformation. Earlier in her career, Monica held senior HR roles at Randstad, where she worked on M&A integration, compensation, and talent strategy across more than 50 countries.
Chief Scientific Officer
Kathrin Bartscher, Chief Scientific Officer, joined NextPharma in 2006. She started her career as a project manager in formulation development and over the years has held various positions in the area of product development. In September 2016 she took over the responsibility for the global NextPharma development activities.
Since 2014 she is board member of the International Association for Pharmaceutical Technology (APV e.V.) and from 2014 to 2023 she held the position of treasurer of APV. Since 2018 she is an external lecturer for the Master of Industrial Pharmacy program at the Heinrich-Heine-University, Duesseldorf. Kathrin holds a PhD in Pharmaceutical Technology.
Head of Quality
Andreas Henkel, Vice President Quality, joined NextPharma in February 2018. Andreas brings with him 20 years of experience in the pharmaceutical industry. Prior to joining NextPharma, he spent in total 15 years at F. Hoffman-La Roche AG (Basle, Switzerland) and Berlin-Chemie AG (Germany) where he held several local and international management positions in Quality and Technical Operations. Andreas holds a Ph.D. in Biophysical Analytics from Max-Planck-Institute for Molecular Physiology.
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.
